Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 11/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359695 | 0.83 | NPSR1 (0.45) | CFTRNPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL30608970 | 0.82 | NPSR1 (0.44) | CFTRNPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL31752450 | 0.82 | NPSR1 (0.44) | CFTRNPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL18405257 | 0.82 | NPSR1 (0.44) | CFTRNPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL18109486 | 0.82 | NPSR1 (0.44) | CFTRNPSR1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11978271 | 0.81 | CFTR (0.44) | CFTRSMN1; SMN2 | |
| SCHEMBL30259615 | 0.81 | CFTR (0.44) | CFTRSMN1; SMN2 | |
| SCHEMBL12687704 | 0.81 | CFTR (0.38) | CFTR | |
| SCHEMBL16505475 | 0.81 | NPSR1 (0.42) | NPSR1KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL30083653 | 0.81 | NPSR1 (0.42) | CFTRNPSR1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724070-A2 | WRN INHIBITORS | Nimbus Wadjet, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4695256-A2 | ERBB2 INHIBITORS | Cogent Biosciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12528806-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12421233-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12344609-B2 | WRN inhibitors | NIMBUS WADJET, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025137599-A1 | WRN INHIBITORS | NIMBUS WADJET, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250206738-A1 | WRN INHIBITORS | NIMBUS DISCOVERY, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-06-05 | — | — | US | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| EP-2344474-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206738-A1 | WRN INHIBITORS | WRN, BLM, RECQL | CFTR 720/4885NPSR1 4764/4885KDM4E 3350/4885 |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CFTR 4536/4885NPSR1 4804/4885KDM4E 673/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | CFTR 4536/4885NPSR1 4804/4885KDM4E 673/4885 |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | PIM1, PIM2, PIM3 | CFTR 1312/4885NPSR1 4477/4885KDM4E 619/4885 |
| US-12421233-B2 | WRN inhibitors | WRN, BLM, RECQL | CFTR 720/4885NPSR1 4764/4885KDM4E 3350/4885 |
| US-12344609-B2 | WRN inhibitors | WRN, BLM, RECQL | CFTR 611/4885NPSR1 4756/4885KDM4E 2662/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | CFTR 810/4885NPSR1 939/4885KDM4E 1694/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | CFTR 4093/4885NPSR1 4157/4885KDM4E 946/4885 |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CFTR 1/4885NPSR1 3829/4885KDM4E 4100/4885 |
| US-12528806-B2 | WRN inhibitors | WRN, RECQL, BLM | CFTR 196/4885NPSR1 4456/4885KDM4E 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.